ER
GSK icon

Enlightenment Research’s GSK GSK Stock Holding History

Enlightenment Research’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,480
Closed -$244K – 131
2022
Q1 		$244K Buy
+4,480
New +$243K 0.32% 100
2019
Q1 		– Sell
-5,120
Closed -$245K – 338
2018
Q4 		$245K Buy
+5,120
New +$252K 0.3% 69

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Enlightenment Research's GSK Position: Q2 2022 in Review

Enlightenment Research sold out of GSK (GSK) in Q2 2022, closing a stake of 4,480 shares — an estimated $244K sold.

Enlightenment Research first reported a position in GSK in Q4 2018 and held it in 2 quarters. The position peaked at $245K in Q4 2018. 901 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

  • Enlightenment Research reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
  • Enlightenment Research sold 4,480 GSK shares in Q2 2022, an estimated $244K.
  • Enlightenment Research first reported a position in GSK in Q4 2018 and held it in 2 quarters.
  • Enlightenment Research's GSK position peaked at $245K in Q4 2018.
  • 901 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Enlightenment Research's 13F filing for Q2 2022, filed 12 Aug 2022.